Key Drivers
- Margin Recovery
- Cash Burn
- High Leverage
AIAI Summary
AUTL has transitioned into an early commercial execution story as AUCATZYL revenue and gross margins improve, but investors should require sustained growth, margins above 50%, and declining cash burn before viewing the highly leveraged company as self-funding.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Margin Recovery
- •Cash Burn
- •High Leverage
AUTL's margins and cash burn improved significantly, but ongoing losses, negative free cash flow, high leverage, and weak book value remain substantial risks despite strong liquidity.
Price Behavior
Key Price Behavior Insights:
- •Strong Uptrend
- •Stretched Momentum
- •Resistance Retest
AUTL's last-month surge to $2.41 remains bullish above $2.28–$2.33 support, but momentum is stretched after retreating from $2.54; a breakout above $2.54 is bullish, while a break below $2.00 would weaken the trend.
Sharp rise from the mid-$1.40s to $2.54 followed by a retreat to $2.41
Sentiment & News
Key News Insights:
- •Strong Sales Momentum
- •Raised Revenue Guidance
- •Expanded Capital Base
Autolus reported accelerating AUCATZYL sales, raised 2026 revenue guidance to $140 million–$150 million, and secured up to $250 million in financing.
The update is positive for Autolus, supporting growth prospects and strengthening financial flexibility
Similar Companies in Healthcare
Other companies in the same sector with AI ratings